COVID-19 Infection Clinical Trial
— HOPICOVOfficial title:
Registry of Management Strategies for Patients With COVID-19 in Healthcare Establishments
The purpose of the study is to describe medical care strategies implemented by healthcare establishments for patients affected by COVID-19
Status | Recruiting |
Enrollment | 2071 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Any adult patient admitted to the establishment for treatment for a SARS-Cov2 infection - Positive RT-PCR or a scanner suggestive of COVID-19 during the stay, or with a positive serology (even if carried out after the patient's discharge) - Hospitalization > 24h - Patients receiving any type of care, whether it is recommended standard care or off-label treatment as part of a therapeutic clinical trial or outside the scope of clinical research Exclusion Criteria: - Opposition to the use of data following written patient information - Patient transferred from another hospital to continue COVID care and whose initial care data is not available |
Country | Name | City | State |
---|---|---|---|
France | Hospital Center Emile Roux | Le Puy-en-Velay |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Emile Roux | Boulogne sur Mer Hospital Center, Centre Hospitalier de Dax, Centre Hospitalier de Montauban, Centre Hospitalier de Saint-Brieuc, Centre Hospitalier de Saint-Lô, Centre Hospitalier de Saint-Malo, Centre Hospitalier de Troyes, Centre Hospitalier de Valence, Centre Hospitalier Henri Duffaut - Avignon, Centre Hospitalier Intercommunal de Mont de Marsan, Centre Hospitalier Intercommunal de Poissy / Saint-Germain, Centre Hospitalier Louis Pasteur, Chartres, Centre Hospitalier Public du Cotentin, Centre Hospitalier William Morey - Chalon sur Saône, Groupe Hospitalier Aube Marne, Groupe Hospitalier La Rochelle Ré Aunis, Médipôle Lyon-Villeurbanne |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Describe management strategies implemented by healthcare establishments for patients with covid-19, depending on the evolution of scientific knowledge and recommendations for specific treatments. | The use of specific treatments or specific care in COVID unit, inclusion in clinical trials, will be combined to report the evolution of French recommendations and scientific literature around the COVID-19. | During the hospitalization | |
Secondary | Describe management strategies to take care depending on the patient | Specific and non specific administered treatments, inclusion in clinical trials, depending on the patients' age, symptoms at admission, comorbidities (including the presence of renal failure, unbalanced diabetes or heart disorder based on laboratory criteria and ECG) will be combined to describe different management strategies to take care depending on the patient. | During the hospitalization | |
Secondary | Compare patients' clinical course who received different management strategies | Comparison of hospitalization time (days), time between the onset and the end of symptoms (days), passage in intensive care and patients' vital status, according to the treatments received (non-specific / standard versus the different specific treatments administered off-label within the framework of clinical trials or not) will be combined to compare the patients' clinical course who received different management strategies | During the hospitalization | |
Secondary | Evaluate the cost of the care | Costs of specific treatments | During the hospitalization | |
Secondary | Evaluate the effectiveness of the care | Hospitalization time and survival status will be combined to evaluate the effectiveness of the care | During the hospitalization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04997551 -
Double Blind Randomized Clinical Trial of Use of Colchicine Added to Standard Treatment in Hospitalized With Covid-19
|
Phase 3 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Completed |
NCT05049226 -
Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine
|
Phase 2 | |
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Terminated |
NCT04455815 -
A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1)
|
Phase 2 | |
Completed |
NCT04662437 -
The Status of Parathyroid Hormone Secretion in Covid-19 Patients
|
||
Recruiting |
NCT05792878 -
Study of COVID-19 Infection and Its Clinical Prognosis in Chronic Hepatitis B Patients With Antiviral Therapy
|
||
Completed |
NCT04659200 -
Thyroid Function Tests and Status of Thyroid Autoantibodies in Covid-19 Patients
|
||
Recruiting |
NCT04470583 -
Evaluating Clinical Parameters of COVID-19 in Pregnancy
|
||
Withdrawn |
NCT04377568 -
Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children
|
Phase 2 | |
Completed |
NCT04848610 -
The Factors That Affect the Infection of COVID-19
|
||
Recruiting |
NCT04582903 -
Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
|
||
Recruiting |
NCT06032000 -
Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)
|
Phase 1 | |
Terminated |
NCT04941703 -
"CHANGE COVID-19 Severity"
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04639466 -
A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection
|
Phase 1/Phase 2 | |
Completed |
NCT04575038 -
CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19
|
Phase 2 | |
Recruiting |
NCT05022446 -
The Impact of COVID-19 on Pulmonary Procedures
|
||
Completed |
NCT04347798 -
IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
|
||
Active, not recruiting |
NCT04650178 -
Well-being in Cancer Patients With Neuropathy During COVID-19 Who Participated in Prior Clinical Trials
|
||
Recruiting |
NCT04169542 -
Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
|